The onset of the COVID-19 pandemic in H1 2020 had a profound effect on the dealmaking landscape in the life sciences sector, stifling M&A but driving strong partnering activity as governments, academia and industry joined forces to find solutions to tackle the virus. It also forced companies to review their operations, re-evaluate their long-term strategies and accelerate portfolio reviews.